MX2018014374A - Tiofeno, método de fabricación y aplicación farmacéutica del mismo. - Google Patents

Tiofeno, método de fabricación y aplicación farmacéutica del mismo.

Info

Publication number
MX2018014374A
MX2018014374A MX2018014374A MX2018014374A MX2018014374A MX 2018014374 A MX2018014374 A MX 2018014374A MX 2018014374 A MX2018014374 A MX 2018014374A MX 2018014374 A MX2018014374 A MX 2018014374A MX 2018014374 A MX2018014374 A MX 2018014374A
Authority
MX
Mexico
Prior art keywords
thiophene
manufacturing
same
pharmaceutical application
preparing
Prior art date
Application number
MX2018014374A
Other languages
English (en)
Inventor
Zhang Yang
Chen Shuhui
Wang Jianfei
Zhu Wenyuan
Original Assignee
Cstone Pharmaceuticals Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceuticals Shanghai Co Ltd filed Critical Cstone Pharmaceuticals Shanghai Co Ltd
Publication of MX2018014374A publication Critical patent/MX2018014374A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invencion describe un tiofeno utilizado como un inhibidor del transportador de acido urico (URAT1) y la aplicacion del tiofeno en la preparacion de un producto farmaceutico para el tratamiento de una enfermedad relacionada con niveles de acido urico anormales, especificamente en la preparacion de un producto farmaceutico para tratar hiperuricemia y artritis gotosa; la invencion esta especificamente relacionada con un compuesto como representado por la Formula (I) (ver fórmula) o una sal farmaceuticamente aceptable del mismo.
MX2018014374A 2016-05-23 2017-05-23 Tiofeno, método de fabricación y aplicación farmacéutica del mismo. MX2018014374A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610343321 2016-05-23
PCT/CN2017/085458 WO2017202291A1 (zh) 2016-05-23 2017-05-23 噻吩化合物及其合成方法和其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2018014374A true MX2018014374A (es) 2019-05-20

Family

ID=60411095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014374A MX2018014374A (es) 2016-05-23 2017-05-23 Tiofeno, método de fabricación y aplicación farmacéutica del mismo.

Country Status (13)

Country Link
US (1) US10829483B2 (es)
EP (1) EP3466946B1 (es)
JP (1) JP6724246B2 (es)
KR (1) KR102244216B1 (es)
CN (1) CN109790155B (es)
AU (1) AU2017270858B2 (es)
BR (1) BR112018074027A2 (es)
CA (1) CA3025078C (es)
ES (1) ES2961901T3 (es)
MX (1) MX2018014374A (es)
NZ (1) NZ749427A (es)
RU (1) RU2709473C9 (es)
WO (1) WO2017202291A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915542B1 (en) 2014-12-23 2023-11-22 Dyve Biosciences, Inc. Formulations for transdermal administration
WO2019055880A2 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. METHOD OF ADMINISTRATION AND TREATMENT
JP6892968B2 (ja) * 2017-11-23 2021-06-23 メッドシャイン ディスカバリー インコーポレイテッド Ｕｒａｔ１阻害剤の結晶形及びその製造方法
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
MX2022004713A (es) * 2019-10-30 2022-05-11 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos.
CN115103840A (zh) 2019-12-20 2022-09-23 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
CN113368067A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的口服药物片剂的方法
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
CN113368073A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的药物制剂的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0810524B8 (pt) * 2007-04-11 2021-05-25 Kissei Pharmaceutical derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado
SI2217577T1 (sl) 2007-11-27 2014-11-28 Ardea Biosciences, Inc. Nove spojine in sestavki ter metode uporabe
KR20110050708A (ko) * 2008-09-04 2011-05-16 아디아 바이오사이언스즈 인크. 요산 수치를 조절하기 위한 화합물, 조성물 및 이들의 사용 방법
WO2012050589A1 (en) * 2010-10-15 2012-04-19 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
AU2013345894B2 (en) 2012-11-14 2017-05-25 Teijin Limited Pyridine derivative
CA2980484C (en) * 2015-03-24 2019-11-26 Shanghai Yingli Pharmaceutical Co., Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
CN105399694B (zh) * 2015-12-11 2017-09-15 浙江京新药业股份有限公司 药物Lesinurad轴手性对映体

Also Published As

Publication number Publication date
EP3466946A1 (en) 2019-04-10
ES2961901T3 (es) 2024-03-14
AU2017270858A1 (en) 2019-01-17
US10829483B2 (en) 2020-11-10
RU2709473C9 (ru) 2020-06-16
CA3025078A1 (en) 2017-11-30
NZ749427A (en) 2019-11-29
KR102244216B1 (ko) 2021-04-26
US20200140423A1 (en) 2020-05-07
BR112018074027A2 (pt) 2019-02-26
JP6724246B2 (ja) 2020-07-15
KR20190009377A (ko) 2019-01-28
CN109790155B (zh) 2022-02-18
AU2017270858B2 (en) 2019-09-19
CA3025078C (en) 2021-04-13
EP3466946A4 (en) 2019-11-06
EP3466946B1 (en) 2023-08-30
CN109790155A (zh) 2019-05-21
RU2709473C1 (ru) 2019-12-18
JP2019519606A (ja) 2019-07-11
WO2017202291A1 (zh) 2017-11-30

Similar Documents

Publication Publication Date Title
NZ749427A (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same
PH12017501160A1 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
PH12018500061A1 (en) Oxysterols and methods of use thereof
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
NZ741318A (en) Compound for treating or preventing hyperuricemia or gout
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
PH12014501711A1 (en) Benzyl sulfonamide derivatives useful as mogat-2 inhibitors
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
PH12016502568A1 (en) Novel heterocyclic compound
PH12017500435A1 (en) A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
WO2017034242A3 (ko) 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
MX2019014438A (es) Derivados de acidos carboxilicos eficaces como inhibidores de la proteina quinasa.
PH12017500124B1 (en) Azole benzene derivative and crystalline form thereof
WO2018080215A8 (en) 3-AMINO ALKYLATED INDOLE DERIVATIVE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF
NZ748746A (en) Pyrazolopyrimidine derivatives as kinase inhibitor
WO2016047967A3 (ko) N-(5-아릴아미도-2-메틸페닐)-5-메틸이소옥사졸-4-카복스아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 fms 키나아제 저해제
TN2014000308A1 (en) Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors